Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Peripherally Induced Regulatory T Cells: Recruited Protectors of the Central Nervous System against Autoimmune Neuroinflammation.

Jones A, Hawiger D.

Front Immunol. 2017 May 9;8:532. doi: 10.3389/fimmu.2017.00532. eCollection 2017. Review.

2.

Dying to protect: cell death and the control of T-cell homeostasis.

Li KP, Shanmuganad S, Carroll K, Katz JD, Jordan MB, Hildeman DA.

Immunol Rev. 2017 May;277(1):21-43. doi: 10.1111/imr.12538. Review.

PMID:
28462527
3.

Flicr, a long noncoding RNA, modulates Foxp3 expression and autoimmunity.

Zemmour D, Pratama A, Loughhead SM, Mathis D, Benoist C.

Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):E3472-E3480. doi: 10.1073/pnas.1700946114. Epub 2017 Apr 10.

PMID:
28396406
4.

Broad induction of immunoregulatory mechanisms after a short course of anti-IL-7Rα antibodies in NOD mice.

Vazquez-Mateo C, Collins J, Fleury M, Dooms H.

BMC Immunol. 2017 Mar 29;18(1):18. doi: 10.1186/s12865-017-0201-4.

5.

Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signaling.

Kumar P, Alharshawi K, Bhattacharya P, Marinelarena A, Haddad C, Sun Z, Chiba S, Epstein AL, Prabhakar BS.

Sci Rep. 2017 Jan 3;7:39751. doi: 10.1038/srep39751.

6.

Singular role for T-BET+CXCR3+ regulatory T cells in protection from autoimmune diabetes.

Tan TG, Mathis D, Benoist C.

Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):14103-14108. Epub 2016 Nov 21.

PMID:
27872297
7.

β-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice.

Manzoor F, Johnson MC, Li C, Samulski RJ, Wang B, Tisch R.

Eur J Immunol. 2017 Jan;47(1):144-154. doi: 10.1002/eji.201646493. Epub 2016 Nov 25.

PMID:
27859048
8.

Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?

Visperas A, Vignali DA.

J Immunol. 2016 Nov 15;197(10):3762-3770. Review.

PMID:
27815439
9.

Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.

Todd JA, Evangelou M, Cutler AJ, Pekalski ML, Walker NM, Stevens HE, Porter L, Smyth DJ, Rainbow DB, Ferreira RC, Esposito L, Hunter KM, Loudon K, Irons K, Yang JH, Bell CJ, Schuilenburg H, Heywood J, Challis B, Neupane S, Clarke P, Coleman G, Dawson S, Goymer D, Anselmiova K, Kennet J, Brown J, Caddy SL, Lu J, Greatorex J, Goodfellow I, Wallace C, Tree TI, Evans M, Mander AP, Bond S, Wicker LS, Waldron-Lynch F.

PLoS Med. 2016 Oct 11;13(10):e1002139. doi: 10.1371/journal.pmed.1002139. eCollection 2016 Oct.

10.

Loss of immune tolerance to IL-2 in type 1 diabetes.

Pérol L, Lindner JM, Caudana P, Nunez NG, Baeyens A, Valle A, Sedlik C, Loirat D, Boyer O, Créange A, Cohen JL, Rogner UC, Yamanouchi J, Marchant M, Leber XC, Scharenberg M, Gagnerault MC, Mallone R, Battaglia M, Santamaria P, Hartemann A, Traggiai E, Piaggio E.

Nat Commun. 2016 Oct 6;7:13027. doi: 10.1038/ncomms13027.

11.

Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives.

Jeffery HC, Braitch MK, Brown S, Oo YH.

Front Immunol. 2016 Sep 6;7:334. doi: 10.3389/fimmu.2016.00334. eCollection 2016. Review.

12.

Regulatory T Cell Numbers in Inflamed Skin Are Controlled by Local Inflammatory Cues That Upregulate CD25 and Facilitate Antigen-Driven Local Proliferation.

Billroth-MacLurg AC, Ford J, Rosenberg A, Miller J, Fowell DJ.

J Immunol. 2016 Sep 15;197(6):2208-18. doi: 10.4049/jimmunol.1502575. Epub 2016 Aug 10.

PMID:
27511734
13.

Hepatic immunophenotyping for streptozotocin-induced hyperglycemia in mice.

Lee YS, Eun HS, Kim SY, Jeong JM, Seo W, Byun JS, Jeong WI, Yi HS.

Sci Rep. 2016 Jul 28;6:30656. doi: 10.1038/srep30656.

14.

Autophagy deficiency in myeloid cells increases susceptibility to obesity-induced diabetes and experimental colitis.

Lee HY, Kim J, Quan W, Lee JC, Kim MS, Kim SH, Bae JW, Hur KY, Lee MS.

Autophagy. 2016 Aug 2;12(8):1390-403. doi: 10.1080/15548627.2016.1184799. Epub 2016 Jun 23.

PMID:
27337687
15.

Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice.

Haddad CS, Bhattacharya P, Alharshawi K, Marinelarena A, Kumar P, El-Sayed O, Elshabrawy HA, Epstein AL, Prabhakar BS.

Autoimmunity. 2016 Aug;49(5):298-311. doi: 10.1080/08916934.2016.1183657. Epub 2016 May 31.

PMID:
27245356
16.

Phenotypical characterization of regulatory T cells in humans and rodents.

Rodríguez-Perea AL, Arcia ED, Rueda CM, Velilla PA.

Clin Exp Immunol. 2016 Sep;185(3):281-91. doi: 10.1111/cei.12804. Epub 2016 Aug 1. Review.

PMID:
27124481
17.

Inhibition of the JAK/STAT Signaling Pathway in Regulatory T Cells Reveals a Very Dynamic Regulation of Foxp3 Expression.

Goldstein JD, Burlion A, Zaragoza B, Sendeyo K, Polansky JK, Huehn J, Piaggio E, Salomon BL, Marodon G.

PLoS One. 2016 Apr 14;11(4):e0153682. doi: 10.1371/journal.pone.0153682. eCollection 2016. Erratum in: PLoS One. 2016;11(6):e0157629.

18.

The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice.

Cucak H, Hansen G, Vrang N, Skarsfeldt T, Steiness E, Jelsing J.

J Diabetes Res. 2016;2016:7484601. doi: 10.1155/2016/7484601. Epub 2016 Feb 3.

19.

The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements.

Procaccini C, Carbone F, Di Silvestre D, Brambilla F, De Rosa V, Galgani M, Faicchia D, Marone G, Tramontano D, Corona M, Alviggi C, Porcellini A, La Cava A, Mauri P, Matarese G.

Immunity. 2016 Feb 16;44(2):406-21. doi: 10.1016/j.immuni.2016.01.028. Erratum in: Immunity. 2016 Mar 15;44(3):712.

20.

Inducing and Administering Tregs to Treat Human Disease.

Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC.

Front Immunol. 2016 Jan 22;6:654. doi: 10.3389/fimmu.2015.00654. eCollection 2015. Review.

Supplemental Content

Support Center